Yujie (Jay) Wen
About Yujie (Jay) Wen
Yujie (Jay) Wen is a Principal Scientist at Bristol-Myers Squibb, specializing in global product quality for CTDO CMC and commercialization, with extensive experience in quality control and research in cellular therapeutics and nephrology.
Title and Role at Bristol-Myers Squibb
Yujie (Jay) Wen is currently serving as Principal Scientist, Global Product Quality, CTDO CMC & Commercialization at Bristol-Myers Squibb. His role is based in the Greater New York City Area. His responsibilities likely involve overseeing product quality and ensuring regulatory compliance during commercialization. Wen's expertise in cellular therapeutics and quality control significantly contributes to the development and implementation of high-quality standards for products at Bristol-Myers Squibb.
Previous Role at Celgene
In 2019, Yujie (Jay) Wen worked for a short period at Celgene as Principal Scientist, Global Product Quality, CTDO CMC & Commercialization in Summit, New Jersey. Although his tenure was brief, lasting only one month, this experience added to his professional journey, enhancing his expertise in product quality and commercialization within the pharmaceutical industry.
Experience at Talaris Therapeutics
Yujie (Jay) Wen previously held the position of Quality Control Scientist at Talaris Therapeutics in Louisville, Kentucky Area. During his 8-month tenure in 2019, Wen contributed to quality control processes, ensuring the integrity and consistency of the therapeutics being developed at Talaris.
Long-term Contributions at Institute for Cellular Therapeutics
From 2007 to 2019, Yujie (Jay) Wen worked as a Quality Control / Research Associate at the Institute for Cellular Therapeutics, University of Louisville. Over his 12-year tenure, Wen made significant contributions to research and quality control within the field of cellular therapeutics, showcasing his extensive experience and commitment to advancing therapeutic interventions.
Academic Background and Research
Yujie (Jay) Wen holds a Doctor of Philosophy (PhD) from Peking University Health Science Center, completed in 2006, where he specialized in Acute Kidney Injury. He also earned a Master of Science (MS) in Diabetic Nephropathy and a Doctor of Medicine (MD) from Southeast University. His extensive academic background provides a solid foundation in both research and clinical settings, particularly within the fields of nephrology and cellular therapeutics.